Prosecution Insights
Last updated: November 20, 2026

Jeanine Anne Goldberg, USPTO Patent Examiner

Listed by the USPTO as GOLDBERG, JEANINE ANNE

Tech Center 3700 • Art Units: 1634 1637 1682 1683 1699 3791

This examiner grants 46% of resolved cases

Analysis

GOLDBERG, JEANINE ANNE is assigned to tech center 3700 and art unit 1634. The record includes 839 resolved cases, a 45.6% allowance rate, and a median of 1276 days to allowance. The 40.7% interview lift indicates a substantial association between interviews and allowance outcomes in the recorded cases.

The listed companies are The Regents of the University of California, Kao Corporation, and Hadasit Medical Research Services and Development Ltd. The listed firms are CASIMIR JONES, S.C., FOLEY & LARDNER LLP, and MARSHALL, GERSTEIN & BORUN LLP. The broad record supports using interview planning as a central part of prosecution strategy for matters assigned to this examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

45.6%
Allow Rate
-24.4% vs TC avg
927
Total Applications
+40.7%
Interview Lift
1276
Avg Prosecution Days
Based on 839 resolved cases, 2023–2026

Rejection Statute Breakdown

23.0%
§101 Eligibility
17.4%
§102 Novelty
19.6%
§103 Obviousness
29.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18551126 BIOMARKERS FOR CONFORMATION OF RIDING TRAITS IN HORSES Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18363344 METHODS, DEVICES, AND SYSTEMS FOR DETERMINING LOW GRADE GLIOMA (LGG) SUBTYPES IDENTIFIED THROUGH MACHINE LEARNING Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18537540 LINKED TRANSCRIPT SEQUENCING Non-Final OA Singular Genomics Systems, Inc.
18591359 ANALYSIS METHOD, KIT, AND DETECTION DEVICE Non-Final OA KABUSHIKI KAISHA TOSHIBA
17402018 GENETIC ABNORMALITIES IN PLASMA CELL DYSCRASIAS Non-Final OA Dana-Farber Cancer Institute, Inc.
18463329 COMPOSITIONS AND METHODS FOR MOLECULAR INVERSION PROBE ASSAYS Non-Final OA AFFYMETRIX, INC.
18241411 COMPOSITIONS AND METHODS FOR DETECTING GYNECOLOGICAL CANCER Non-Final OA Mayo Foundation for Medical Education and Research
18577231 DIAGNOSING INFLAMMATORY BOWEL DISEASES Non-Final OA SHEBA IMPACT LTD.
18251528 MULTIPLEX DETECTION OF BACTERIAL RESPIRATORY PATHOGENS Final Rejection Becton, Dickinson and Company
18416592 METHOD FOR PREPARING NUCLEIC ACID SAMPLE Non-Final OA KAO Corporation
18015311 METHOD FOR DETECTING SEVERITY OF ATOPIC DERMATITIS Non-Final OA KAO CORPORATION
17922565 METHOD FOR DETECTING ATOPIC DERMATITIS Non-Final OA KAO CORPORATION
18008146 TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS Non-Final OA CEDARS-SINAI MEDICAL CENTER
18285876 ISOTHERMAL AMPLIFICATION-BASED DETECTION OF SHRIMP PATHOGENS Final Rejection ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
18691704 microRNA BIOMARKERS Non-Final OA IMPERIAL COLLEGE INNOVATIONS LIMITED
18699569 CD274 REARRANGEMENTS AS PREDICTORS OF RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY Non-Final OA Foundation Medicine, Inc.
18391216 PERIANAL SWAB PCR PANEL, METHODS, DEVICE, AND KITS Non-Final OA IDEXX Laboratories, Inc.
18291113 USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE Non-Final OA Georgetown University
17994090 MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES Non-Final OA The Rockefeller University
18532745 COMPOSITIONS AND METHODS FOR MUTATIONS ASSOCIATED WITH SUDDEN UNEXPECTED DEATH IN PEDIATRICS (SUDP) Final Rejection The Children's Medical Center Corporation
18270409 METHODS AND KITS FOR DETECTING A RISK FOR DEVELOPING NEUROLOGICAL OR NEUROPHYSIOLOGICAL DISORDERS Final Rejection Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
17794228 BACTERIAL QUANTIFICATION METHOD Final Rejection Microbio Pty Ltd
18044989 TOOLS & METHODS USEFUL FOR DETECTION OF LACTOSE INTOLERANCE AND USES THEREOF Final Rejection Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Jeanine Anne Goldberg's allowance rate?

45.6% of resolved applications examined by Jeanine Anne Goldberg were allowed (839 resolved cases), compared with 30.2% across Art Unit 1634 over the last five years.

Does an interview help with examiner Jeanine Anne Goldberg?

This examiner's interview lift is +40.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Jeanine Anne Goldberg take to allow a patent?

Applications allowed by Jeanine Anne Goldberg took 1,276 days on average from filing to allowance.

Which art unit does examiner Jeanine Anne Goldberg work in?

Jeanine Anne Goldberg examines applications in Art Unit 1634 in Tech Center 3700 (Medical Devices & Mechanical Engineering).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month